Biotech Values

[masterlongevity]

"The most significant value driver, however, is anti- VEGF drug Eylea following positive FDA panel recommendation for approval and a potential $3.5B opportunity in eye disease. Expert feedback suggests that superior efficacy and less frequent dosing should position Eylea favorably to $4B brand Lucentis, and we expect HARBOR and CATT two- year data to confirm a differentiated profile."



I think he's smoking crack